Related to Tolerx and GSK Suspend Second Phase III Diabetes Trial as Defend-1 Otelixizumab Study Fails

• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• GSK Obtains Rights to Delphi’s Antibiotic-Free Tech for Recombinant Vaccines
  
• Prosensa Earns £7.5M Milestone from GSK through Antisense DMD Drug Deal
  
• GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug
  
• GSK Reports Japanese Clearance for ITP Drug as Partner Ligand Gets $2M in Govt Grants
  
• Phase III Data Leads Intercell to Shelve Late-Stage Traveler’s Diarrhea Vaccine Patch
  
• GSK Pays Impax $11.5M Up Front for Non-U.S. Rights to Late-Stage PD Therapy
  
• GSK to Use BioClinica Tool to Manage Clinical Trials
  
• GSK Licenses Immutep’s T-Cell Depleting Antibodies for Autoimmune Diseases
  
• GSK Pays Epizyme $20M Up Front as Part of Histone Methyltransferase Inhibitor Deal
  
• GSK and McGill University Partner to Develop Treatment for Cystic Fibrosis
  
• AFFiRiS Receives €3.5M from GSK with Preclinical Success in Alzheimer Vaccine Alliance
  
• GSK Nixes Neuroscience Collaboration with Targacept
  
• FDA Green-Lights HGS and GSK’s Systemic Lupus Erythematosus Drug Benlysta
  
• XenoPort and GSK’s Treatment for Restless Legs Syndrome Cleared in the U.S.
  
• Isis Wins $5M from GSK with Launch of First Phase I Study
  
• FDA Clears Valeant and GSK’s Potiga for Partial-Onset Seizures in Adults
  
• Diamyd Discontinues U.S. Phase III Trial with Type 1 Diabetes Product
  
• Unigene and GSK Broaden Deal in Anticipation of Phase III Trial in Postmenopausal Osteoporosis